n
a
v
Portfolio
Genetics
AmplideX® Fragile X Dx & Carrier Screen Kit
AmplideX® mPCR FMR1 Kit
AmplideX® PCR/CE FMR1 Kit
AmplideX® FMR1 Controls
Xpansion Interpreter®
AmplideX® PCR/CE
SMN1/2
Plus Kit
AmplideX® PCR/CE
CFTR
Kit
AmplideX® PCR/CE C9orf72 Kit
AmplideX® PCR/CE
DMPK
Kit
AmplideX® PCR/CE
HTT
Kit
AmplideX® TRIO
Oncology
QuantideX® qPCR BCR-ABL IS Kit
QuantideX® qPCR BCR-ABL minor Kit
MolecularDx Controls
Catalog of Armored Products
SARS CoV-2 Controls
Made-To-Order Armored and Nucleic Acid
Molecular Assay Reagents
Custom & Companion Diagnostics
Partnered R&D
CAP-Accredited CLIA Lab
CTA Testing Site
Validated Platforms & Assays
Companion Diagnostics
Enabling Technologies
Assay Chemistries
Bioinformatics
Product Development Process
Resources
Publications
Articles
Whitepapers
Posters
Disease Information
Fragile X Syndrome
Dementia
Chronic Myeloid Leukemia (CML)
Other Resources
Videos
Carrier Screening Guide
Safety Data Sheets
Sales Contacts
Our Culture
Employee Spotlights
Culture & Heritage
Sales Contacts
About
Leadership Team
Culture and Heritage
News
Upcoming Events
Business Development
Contact
Careers
Search
Asuragen Molecular Diagnostics Publications
Home
Asuragen Molecular Diagnostics Publications
Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways
Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways
May 3, 2008
Back To
Top
